T1	Participants 64 94	randomized, double-blind study
T2	Participants 213 260	patients with bone marrow transplantation (BMT)
T3	Participants 385 465	66 patients with 43 hematologic and 23 solid malignancies (21 breast carcinomas)
T4	Participants 761 799	Patients with hematologic malignancies
T5	Participants 956 988	Patients with solid malignancies
